Female Health Co  

(Public, NASDAQ:FHCO)   Watch this stock  
Find more results for FHCO
-0.04 (-3.01%)
Real-time:   3:48PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.29 - 1.32
52 week 1.16 - 2.75
Open 1.32
Vol / Avg. 31,979.00/79,961.00
Mkt cap 37.76M
P/E 11.00
Div/yield     -
EPS 0.12
Shares 29.05M
Beta 1.14
Inst. own 11%
Jul 28, 2016
Q3 2016 Female Health Co Earnings Call - 11:15AM EDT - Add to calendar
Jul 28, 2016
Q3 2016 Female Health Co Earnings Release Add to calendar
Jul 13, 2016
Female Health Co at Cantor Fitzgerald Healthcare Conference
May 12, 2016
Female Health Co at Drexel Hamilton Micro-Cap Investor Forum
Apr 28, 2016
Q2 2016 Female Health Co Earnings Call
Apr 28, 2016
Q2 2016 Female Health Co Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin 0.73% 13.33%
Operating margin 1.48% 20.30%
EBITD margin - 21.81%
Return on average assets 0.35% 12.57%
Return on average equity 0.40% 14.20%
Employees 180 -
CDP Score - -


515 N State St Ste 2225
CHICAGO, IL 60654-4863
United States - Map
+1-312-5959123 (Phone)
+1-312-5959122 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


The Female Health Company is engaged in development, manufacture, and marketing of consumer healthcare products. The Company manufactures, markets and sells FC2 Female Condom (FC2). Its FC2 is primarily used for disease prevention and family planning. The Company's FC2 product facilitates dual protection for women against both unintended pregnancy and sexually transmitted infections (STIs), including human immunodeficiency virus (HIV) and acquired immune deficiency syndrome (AIDS). Public health sector is the Company's main market. It offers FC2 in over 140 countries. It also offers male condoms. It offers FC2 from a nitrile polymer formulation. FC2 consists of a soft, loose fitting sheath and two rings: an external ring of rolled nitrile and a loose internal ring made of flexible polyurethane. FC2's soft sheath lines the vagina, preventing skin-to-skin contact during intercourse. Its external ring remains outside the vagina, partially covering the external genitalia.

Officers and directors

Overton B. Parrish Jr. Chairman of the Board, Chief Executive Officer
Age: 82
Bio & Compensation  - Reuters
Michele Greco Chief Financial Officer, Executive Vice President, IR Contact Officer
Age: 57
Bio & Compensation  - Reuters
Martin Clifford Tayler Executive Vice President - Global Operations
Age: 47
Bio & Compensation  - Reuters
William R. Gargiulo Jr. Secretary, Independent Director
Age: 86
Bio & Compensation  - Reuters
David R. Bethune Independent Director
Age: 75
Bio & Compensation  - Reuters
Donna Felch Independent Director
Age: 68
Bio & Compensation  - Reuters
Mary Margaret Frank Ph.D. Independent Director
Age: 47
Bio & Compensation  - Reuters
Andrew S. Love Jr. Independent Director
Age: 72
Bio & Compensation  - Reuters
Sharon Meckes Independent Director
Age: 50
Bio & Compensation  - Reuters